Cargando…
Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension
Resistant hypertension (RH) is defined as the failure to achieve blood pressure control despite using triple combination therapy with a renin-angiotensin system inhibitor (RAS-i), a calcium antagonist, and a diuretic. The endothelin (ET) system is implicated in the regulation of vascular tone, prima...
Autores principales: | Boutari, Chrysoula, Siskos, Fotios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051756/ https://www.ncbi.nlm.nih.gov/pubmed/36983961 http://dx.doi.org/10.3390/life13030806 |
Ejemplares similares
-
Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension
por: Heidari Nejad, Sayeh, et al.
Publicado: (2023) -
Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
por: Angeli, Fabio, et al.
Publicado: (2021) -
Decreasing Lean Body Mass with Age: Challenges and Opportunities for Novel Therapies
por: Boutari, Chrysoula, et al.
Publicado: (2017) -
Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease
por: Boutari, Chrysoula, et al.
Publicado: (2018) -
A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on
por: Boutari, Chrysoula, et al.
Publicado: (2022)